Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427351 | 1.00 | JAK3 (0.44) | JAK3PDE4BSTK10SLKPABPC1 | |
| SCHEMBL5428504 | 0.88 | PDGFRB (0.42) | JAK3PDE4BSTK10SLKCCKBR | |
| SCHEMBL5428509 | 0.88 | PDGFRB (0.42) | JAK3PDE4BSTK10SLKCCKBR | |
| SCHEMBL5430072 | 0.86 | ADORA1 (0.42) | JAK3PDE4BSTK10SLKPABPC1 | |
| SCHEMBL5430077 | 0.86 | ADORA1 (0.42) | JAK3PDE4BSTK10SLKPABPC1 | |
| SCHEMBL5172633 | 0.86 | NPC1 (0.43) | JAK3PDE4BSTK10SLKPABPC1 | |
| SCHEMBL5432246 | 0.86 | NPC1 (0.43) | JAK3PDE4BSTK10SLKPABPC1 | |
| SCHEMBL7007610 | 0.85 | PABPC1 (0.44) | STK10SLKPABPC1TUBB4ATUBB | |
| SCHEMBL7007615 | 0.85 | PABPC1 (0.44) | STK10SLKPABPC1TUBB4ATUBB | |
| SCHEMBL5196258 | 0.85 | HTT (0.46) | JAK3PDE4BSTK10SLKPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815439-B2 | PYRROLO(2,3-B)PYRIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-11-09 | — | — | US | claimed |
| EP-1180105-B1 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-05-14 | — | — | EP | claimed |
| JP-2003502280-A | — | — | 2003-01-21 | — | — | JP | claimed |
| EP-1180105-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-02-20 | — | — | EP | claimed |
| WO-2000055159-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-09-21 | — | — | WO | claimed |
| US-20070213403-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | FORSKARPATENT I SYD AB (SE) | 2007-09-13 | — | — | US | disclosed |
| EP-1773309-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | Forskarpatent i Syd AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| WO-2006004545-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | FORSKARPATENT I SYD AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| US-6815439-B2 | PYRROLO(2,3-B)PYRIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-11-09 | — | — | US | disclosed |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | HARRIS PHILIP ANTHONY (US) | 2004-04-15 | — | — | US | disclosed |
| US-6624171-B1 | Useful as cyclin dependent kinase 11 inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar- palmar syndrome, mucositis) induced by chemotherapy and/or radiation therapy | SMITHKLINE BEECHAM CORPORATION | 2003-09-23 | — | — | US | disclosed |
| EP-1180105-B1 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-05-14 | — | — | EP | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-1180105-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000055159-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | JAK3 29/4885PDE4B 4504/4885STK10 309/4885 |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | CCNI, AZI2, CDKN1A | JAK3 294/4885PDE4B 2777/4885STK10 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.